Study of DCR-A1AT in Healthy Adult Volunteers

Dicerna Pharmaceuticals

Status and phase

Completed

Phase 1

Conditions

Alpha 1-Antitrypsin Deficiency

Treatments

Drug: belcesiran

Drug: Placebo

Study type

Interventional

Funder types

Industry

Identifiers

NCT04174118

DCR-A1AT-101

Details and patient eligibility

About

This is a research study to test an experimental study drug (belcesiran, also known as DCR-A1AT). This drug is being tested to see if it helps people with a rare condition known as Alpha-1 Antitrypsin Deficiency, or A1ATD. Prior to initiation of this study belcesiran had not yet been tested in humans. All study participants will be randomly assigned to either receive the study drug or a placebo. This will allow for the sponsor to compare the effects of the study drug with that of the placebo. A placebo looks like the study drug but does not contain any of the study drug.

The main purpose of the first part of the study is to evaluate the safety profile of the study drug in people who do not have A1ATD. This part of the study will also help find the dose of the study drug that has an acceptable safety profile for testing.

Full description

A1ATD- associated liver disease is a progressive Alpha-1 Antitrypsin-Deficiency Associated Liver Disease condition resulting in liver fibrosis, cirrhosis, and hepatocellular carcinoma. The lack of functional A1AT in individuals with PiZZ genotype, in conjunction with other precipitating factors, can lead to unchecked activity in neutrophil elastases in the alveoli; causing emphysema and chronic obstructive pulmonary disease (COPD). This loss-of-function mechanism can be addressed with intravenous augmentation therapy, which aims to substitute the missing A1AT by infusing alpha1 proteinase inhibitor (A1PI), purified from pooled human plasma.

While augmentation therapy can address the loss of A1AT in the lungs, no treatment exists for the associated liver disease.

Given the severity of the disease, with approximately 10% of affected patients developing liver cirrhosis and a subgroup of those patients in need of liver transplantation, and lack of an effective treatment that addresses the toxic hepatic "gain-of-function" mechanism, there is an urgent unmet medical need to develop a therapy that can help in this particular patient population.

Enrollment

30 patients

Sex

All

Ages

18 to 55 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Male or Female aged 18 to 55 years, inclusive. Female participants must be either surgically sterile or postmenopausal. No women of childbearing potential are eligible for enrollment.
Overtly Healthy, as determined by the investigator.
Serum A1AT protein concentration >100 mg/dL
Adequate forced expiratory volume in one second (FEV1) and adequate FEV1/forced vital capacity (FVC) ratio
Non-smokers with a <2 pack-year history and smoking cessation for at least 6 months with a negative urinary cotinine test a screening

Exclusion criteria

Presence of any condition or comorbidities that would interfere with study compliance or data interpretation or potentially affect participant safety
Clinically significant abnormal laboratory tests
Received an experimental drug within past 4 months
Prior to use of RNAi drug or oligonucleotide-based therapy
Known human immunodeficiency virus (HIV), hepatitis C virus (HCV), or Hepatitis B (HBV)
Serum creatinine or estimated glomerular filtration rate (eGFR) outside normal reference ranges.